Core Viewpoint - Hong Kong Pharma Digital Technology Holdings Limited (HKPD) successfully passed all proposals at its 2025 annual meeting, indicating a strategic shift and governance updates for the company [1][2][3]. Group 1: Shareholder Proposals - Proposal No. 1 involved the re-election of five directors to serve until the 2026 Annual Meeting [1]. - Proposal No. 2 ratified the appointment of Onestop Assurance PAC as the independent registered public accounting firm for the fiscal year ending March 31, 2026 [1]. - Proposal No. 3 increased the authorized share capital from US$100,000 to US$1,000,000, allowing for a total of 1,000,000,000 ordinary shares [1]. Group 2: Share Structure Changes - Proposal No. 4 re-designated and re-classified the company's shares into Class A and Class B ordinary shares [2]. - Proposal No. 5 approved a Reverse Share Split and Share Consolidation of the company's issued and outstanding ordinary shares [2]. Group 3: Corporate Identity and Governance - Proposal No. 6 changed the company's name to "Cellyan Biotechnology Co., Ltd" and its foreign name to "生研生物公司" [3]. - Proposal No. 7 adopted the fourth amended and restated memorandum and articles of association [3]. - Proposal No. 8 involved the repurchase of 7,150,000 Class A Ordinary Shares and the issuance of Class B Ordinary Shares [3]. - Proposal No. 9 approved the 2025 Equity Incentive Plan [3]. Group 4: Company Overview - HKPD specializes in OTC pharmaceutical cross-border e-commerce supply chain services through its subsidiary, Joint Cross Border Logistics Company Limited [4]. - The company also engages in OTC pharmaceutical cross-border procurement and distribution via its subsidiary, V-Alliance Technology Supplies Limited [4]. - Joint Cross Border provides a comprehensive service offering, including product procurement, logistics, and delivery for Mainland Chinese customers seeking OTC pharmaceutical products [5][6].

Core Points - The company, Cypherpunk Technologies, Inc., formerly known as Leap Therapeutics, Inc., held a virtual Special Meeting of Stockholders on December 15, 2025 [1] - The meeting agenda included several proposals for stockholder approval [2] Proposal Summaries - A proposal to amend the company's Certificate of Incorporation to increase the total number of shares from 250 million to 500 million, with 490 million designated as common stock [3] - A proposal to authorize the Board to amend the Certificate of Incorporation for a reverse stock split at a ratio between 1:5 and 1:20, to be executed at the Board's discretion within one year [4] - A proposal to adopt a new 2025 Equity Incentive Plan [4] - A proposal to allow the company to issue shares exceeding 19.99% of the outstanding common stock to comply with NASDAQ listing rules upon the exercise of certain warrants [5]

Core Viewpoint - FST Corp. has successfully approved its 2025 Equity Incentive Plan during the Annual General Meeting of Shareholders, which is expected to support the company's growth in 2026 and beyond [1][3]. Shareholder Vote - The shareholder vote resulted in 35,658,358 Common Stock shares in favor of the Incentive Plan and only 2,999 shares against it, with no abstentions. This represents a significant majority of the total voting capital stock [2]. Purpose of the Incentive Plan - The 2025 Equity Incentive Plan aims to attract and retain employees, directors, and consultants, aligning their interests with those of the shareholders and promoting the company's business success [3]. Company Overview - FST Corp., founded in 1989, specializes in manufacturing and selling golf club shafts and related items, serving various customers including golf equipment brands and consumers through its KBS Golf Experience retail outlets. The company has established a strong global brand presence and competitive advantages in the golf industry [4]. Growth Strategies - The company's current growth strategies are focused on expanding into under-tapped golf shaft markets, positioning FST for future growth [4].

Group 1 - Netcapital Inc. announced the grant of an inducement restricted stock award of 1,000,000 shares of common stock to a new employee under the 2023 Omnibus Equity Incentive Plan [1] - The 2023 Equity Incentive Plan allows for the issuance of equity awards in the form of inducement grants in accordance with Nasdaq Listing Rule 5635(c) [2] - The Restricted Stock Award will vest based on the company's revenue from February 1, 2026, to January 31, 2027, with specific revenue thresholds determining the vesting percentage [3] Group 2 - Netcapital Inc. is a fintech company that provides a platform for private companies to raise capital online and offers private equity investment opportunities [4] - The company's consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies [4] - Netcapital's funding portal is registered with the U.S. Securities & Exchange Commission (SEC) and is a member of the Financial Industry Regulatory Authority (FINRA) [4]

Core Points - Azarga Metals Corp. awarded a total of 916,667 restricted share units (RSUs) to a consultant under its Equity Incentive Plan [1] Group 1 - The total number of RSUs awarded is 916,667 [1]

Financial Data and Key Metrics Changes - The company held its 2025 Annual General Meeting, where various proposals were presented for stockholder voting, including a reverse stock split and reincorporation [1][2][3] - The preliminary report indicated that all proposals, including the amendment to the equity incentive plan and the issuance of shares to Streeterville Capital, were approved by a majority of votes [12][13][14][15] Business Line Data and Key Metrics Changes - Specific financial data and performance metrics for individual business lines were not disclosed in the meeting [1][2][3] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [1][2][3] Company Strategy and Development Direction - The company proposed a reverse stock split to potentially enhance its stock price and market perception, with a range of 1-for-2 to a maximum of 1-for-10 [9][13] - The reincorporation from Delaware to Nevada was aimed at potentially benefiting from a more favorable regulatory environment [10][13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [1][2][3] Other Important Information - The meeting included the election of seven directors, with all nominated candidates successfully elected [12] - The company plans to increase the number of shares authorized for issuance under its equity incentive plan to 5 million [14] Summary of Q&A Session - No Q&A session was documented in the provided meeting records [1][2][3]

Financial Data and Key Metrics Changes - The stockholders approved the proposal to grant discretionary authority to the Board of Directors for a reverse stock split within a range of 1-for-2 to a maximum of 1-for-10, indicating a strategic move to potentially enhance share value [12][13][14] - The company successfully ratified the selection of M&K CPAs as the independent registered public accounting firm for the fiscal year ending December 31, 2025, ensuring compliance and transparency in financial reporting [15] Business Line Data and Key Metrics Changes - The amendment to the 2022 equity incentive plan to increase the number of shares authorized for issuance to 5 million was approved, which may impact employee compensation and retention strategies [14] Market Data and Key Metrics Changes - The approval of the issuance of shares to Streeterville Capital, LLC, in prepaid financing transactions that may collectively equal or exceed 20% of the issued and outstanding shares indicates a significant capital raise strategy [14] Company Strategy and Development Direction - The company is pursuing a reincorporation from Delaware to Nevada, which may provide more favorable business regulations and tax benefits [13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting, focusing instead on the proposals and voting results Other Important Information - The meeting concluded with the election of seven directors, ensuring continuity in governance and strategic direction [12][13] Summary of Q&A Session - There were no recorded questions or answers during the meeting, as the focus was primarily on the proposals and voting outcomes

Core Insights - LB Pharmaceuticals has granted an equity award to James Rawls, the new Senior Vice President of Regulatory Affairs, as an inducement for his employment with the company [1][2] - The equity award consists of an option to purchase 90,000 shares at an exercise price of $14.61, with a vesting schedule over four years [2] - LB-102, the company's lead product candidate, is advancing into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression, showing promising results in earlier trials [3][4] Company Overview - LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [4] - The company aims to leverage the therapeutic potential of LB-102, which could become the first benzamide antipsychotic approved for neuropsychiatric disorders in the U.S. [4] - If approved, LB-102 may provide a significant alternative to existing treatments for schizophrenia and bipolar depression [4]

Core Points - Rivian has awarded its CEO RJ Scaringe a new performance-based stock award potentially worth around $5 billion if all goals are met [1] - Scaringe's annual salary has been doubled to $2 million, and he received a 10% stake in Rivian's spinout Mind Robotics [1] - The new compensation package was announced shortly after Tesla's shareholders approved a $1 trillion compensation package for Elon Musk [2] Group 1 - Unlike Musk's compensation, Scaringe's new award does not require shareholder approval [3] - The Rivian board's compensation committee canceled a previous performance award due to the "unlikeliness" of Scaringe meeting the required goals [4] - The previous award included 20,355,946 stock options tied to stock price increases, which became difficult to access as Rivian's stock price fell significantly [5] Group 2 - Rivian's stock peaked at around $129 post-IPO in November 2021 but fell to around $30 within six months, typically trading between $10 and $20 in subsequent years [5] - The cancellation of the previous award was attributed to a "lack of incentive" for Scaringe, prompting the issuance of the new award [5][8] - The new performance grant is structured to ensure Scaringe only benefits if the company delivers significant value to shareholders, with a potential $32 billion value addition required for him to see any payout [8][9] Group 3 - The new performance award allows Scaringe to access a maximum of 36,500,000 shares over ten years, potentially increasing his ownership from 1% to 4% of Rivian [10] - 22 million of the stock options are tied to stock price milestones, with Scaringe earning shares as the stock price increases from $40 to $140 [10] - The remaining 14,500,000 stock options are contingent on achieving specific adjusted operating income and cash flow targets, with a strike price of $15.22 per share [11]

Core Points - Asante Gold Corporation held its annual general and special meeting of shareholders on October 21, 2025, with approximately 52% of outstanding common shares represented [1] - All matters presented for approval by management were duly authorized and approved, including the fixing of the number of directors, appointment of auditors, and approval of incentive plans [1][3] Voting Results - The resolution to fix the number of directors at seven was approved with 373,256,704 votes for (100%) and 1,605 votes against [2] - The appointment of auditors received 373,256,704 votes for (100%) with 1,605 votes withheld [2] - The Omnibus Equity Incentive Plan was approved with 349,100,456 votes for (99.68%) and 1,117,932 votes against [2] - The Employee Share Purchase Plan was approved with 320,412,590 votes for (91.49%) and 29,805,798 votes against [2] Election of Directors - Bashir Akwasi Ahmed was elected with 281,855,663 votes for (80.48%) and 68,362,725 votes withheld [2] - David Anthony was elected with 327,736,313 votes for (93.58%) and 22,482,075 votes withheld [2] - Malik Easah was elected unanimously with 350,217,663 votes for (100%) [2] - Other directors elected include Alex Heath, Alireza Abbassi Monjezi, Roger Norwich, and Alexander Smirnov with varying levels of support [2] Security Based Compensation Plans - Shareholders approved the Omnibus Plan, which is a "rolling" 10% plan allowing for various types of equity grants [5] - The Employee Share Purchase Plan (ESPP) is a "fixed" plan allowing for the issuance of up to 6,000,000 common shares to eligible employees [5] - The total number of common shares reserved for these plans must not exceed 10% of the company's total issued and outstanding common shares [5] Company Overview - Asante Gold Corporation is engaged in gold exploration, development, and operations, with projects and mines located in Ghana [6] - The company operates the Bibiani and Chirano Gold Mines and is conducting studies at the Kubi Gold Project [6] - Asante is exploring additional projects including Keyhole, Fahiakoba, and Betenase, all situated in Ghana's Golden Triangle [6]